Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $287000.0.

  • Krystal Biotech's Other Non-Current Assets rose 2424.24% to $287000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $287000.0, marking a year-over-year increase of 2424.24%. This contributed to the annual value of $287000.0 for FY2025, which is 2424.24% up from last year.
  • Krystal Biotech's Other Non-Current Assets amounted to $287000.0 in Q4 2025, which was up 2424.24% from $333000.0 recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Other Non-Current Assets registered a high of $402000.0 during Q1 2023, and its lowest value of $62000.0 during Q3 2021.
  • For the 5-year period, Krystal Biotech's Other Non-Current Assets averaged around $211300.0, with its median value being $204000.0 (2022).
  • Per our database at Business Quant, Krystal Biotech's Other Non-Current Assets surged by 33783.78% in 2022 and then tumbled by 5578.95% in 2024.
  • Krystal Biotech's Other Non-Current Assets (Quarter) stood at $74000.0 in 2021, then skyrocketed by 337.84% to $324000.0 in 2022, then decreased by 18.83% to $263000.0 in 2023, then fell by 12.17% to $231000.0 in 2024, then increased by 24.24% to $287000.0 in 2025.
  • Its Other Non-Current Assets was $287000.0 in Q4 2025, compared to $333000.0 in Q3 2025 and $197000.0 in Q2 2025.